Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The value of screening.

R R Love, A E Camilli

    Cancer
    |July 15, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Early cancer screening can improve outcomes, but requires careful evaluation of cancer characteristics, test accuracy, and program benefits. Assessing screening program value involves complex analysis of costs versus demonstrated reductions in disease and death.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Public health oncology: a framework for progress in low- and middle-income countries.

    Annals of oncology : official journal of the European Society for Medical Oncology·2012
    Same author

    Improving outcomes from breast cancer in a low-income country: lessons from bangladesh.

    International journal of breast cancer·2012
    Same author

    Family history, BRCA mutations and breast cancer in Vietnamese women.

    Clinical genetics·2010
    Same author

    Survivors of breast cancer.

    The New England journal of medicine·2001
    Same author

    The effects of tamoxifen on the vaginal epithelium in postmenopausal women.

    Journal of women's health & gender-based medicine·2000
    Same author

    Symptoms associated with oophorectomy and tamoxifen treatment for breast cancer in premenopausal Vietnamese women.

    Breast cancer research and treatment·2000
    Same journal

    Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

    Cancer·2026
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Preventive Medicine
    • Health Services Research

    Background:

    • Early cancer diagnosis through screening is presumed to improve patient outcomes.
    • However, definitive clinical proof of benefit is often lacking for many cancers.

    Purpose of the Study:

    • To outline critical factors for evaluating the potential value of cancer screening efforts.
    • To discuss characteristics of cancers, screening tests, and programs that favor successful implementation.

    Main Methods:

    • Review of criteria for identifying cancers suitable for screening (prevalence, preclinical phase, treatability).
    • Assessment of desirable qualities for screening tests (sensitivity, specificity, cost, risk).
    • Consideration of evaluation metrics for screening programs (morbidity/mortality reduction, study design).

    Related Experiment Videos

    Main Results:

    • Favorable cancers for screening have high prevalence, long preclinical phases, and benefit from early treatment.
    • Effective screening tests are sensitive, specific, low-cost, and low-risk.
    • Program evaluation requires assessing demonstrable health improvements, often via randomized controlled trials.

    Conclusions:

    • The value of cancer screening is complex, depending on cancer biology, test performance, and program outcomes.
    • Interpreting screening program data requires careful consideration of multidimensional costs and benefits.
    • Comparative analysis with other health interventions aids in decision-making regarding screening program worth.